Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.-Reference-Cited by-同舟云学术

Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.

Published:1987-06 Issue:6 Volume:23 Page:753-757
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:British Journal of Clinical Pharmacology

Author:

Barre J,Mallat A,Rosenbaum J,Deforges L,Houin G,Dhumeaux D,Tillement JP

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1987.tb03111.x/fullpdf

Reference13 articles.

1. Intersubject and dose-related variability after intravenous administration of erythromycin;Austin;Br. J. clin. Pharmac.,1980

2. Decreased α1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding;Barré;Br. J. clin. Pharmac.,1984

3. Modifications pratiques concernant le dosage des antibiotiques en clinique;Chabbert;Rev. franç. Etud. clin. Biol.,1957

4. Biliary excretion of erythromycin after parenteral administration;Chelvan;Br. J. clin. Pharmac.,1979

5. Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects;Hall;J. clin. Pharmac.,1982

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prokinetics‐safety and efficacy: The European Society of Neurogastroenterology and Motility/The American Neurogastroenterology and Motility Society expert review;Neurogastroenterology & Motility;2024-03-10

2. Induction of open-form bile canaliculus formation by hepatocytes for evaluation of biliary drug excretion;Communications Biology;2023-08-22

3. Pharmacokinetics, PK/PD analysis and placental transfer of erythromycin administered to pregnant goats;Small Ruminant Research;2023-02

4. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist;Clinical Pharmacokinetics;2021-05-18

5. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment;Basic & Clinical Pharmacology & Toxicology;2019-05-24